FDA Accepts Priority Review Of Biologics License Application For ltragenyx Pharmaceutical's DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia

Ultragenyx Pharmaceutical, Inc. +3.98% Pre

Ultragenyx Pharmaceutical, Inc.

RARE

24.57

24.57

+3.98%

0.00% Pre

If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.